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From June to September 2012, 500 urine samples were recovered from patients with urinary tract infections (UTI) due to Gram-
negative bacilli (>104 leukocytes/ml and>105 Gram-negative isolates/ml) who visited the University hospital Bicêtre (France).
They were challenged with extended-spectrum--lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) using the rapid di-
agnostic ESBL NDP test. Results of the ESBL NDP test were compared to the results of the double-disc susceptibility test (DDST)
performed on solid-agar plates and molecular identiﬁcation of the-lactamase genes. Among the 450 nonduplicate urine sam-
ples, 11.3% were positive for ESBL-E by using the DDST, the ESBL determinants being mostly of the CTX-M type (CTX-M-15)
according to molecular testing. Results of the ESBL NDP test were obtained within 15 min. The sensitivity and speciﬁcity of the
ESBL NDP test were 98% and 99.8%, respectively, whereas the positive and negative predictive values of this test were 98% and
99.8%, respectively. A perfect correlation between cefotaxime resistance and positivity of the ESBL NDP test was observed.
Therefore, the ESBL NDP test offers a powerful tool for a rapid identiﬁcation of ESBL-E and associated resistance to expanded-
spectrum cephalosporins. It may be useful in particular for guiding ﬁrst-line antibiotic therapy.
Urinary tract infections (UTIs) are the most prevalent infec-tious diseases, with an estimated overall incidence of 18/1,000
persons per year in theUnited States (1). According to the Centers
for Disease Control and Prevention, UTIs that are mostly due to
Escherichia coli account for more than 8.6 million visits to health
care professionals each year in theUnited States (1, 2). In addition,
multidrug resistance is now emerging worldwide among Gram-
negative organisms, which are mostly responsible for UTIs (2).
One of the most important emerging resistance traits corre-
sponds to resistance to broad-spectrum -lactams in Enterobacte-
riaceae, which is mainly associated with acquired ESBLs of the
CTX-M type (ESBL-E) (3, 4). Hence, ESBL-E are usually resistant
to most -lactams except cefoxitin and carbapenems. Therefore,
efﬁcient treatment of those infections is becoming challenging
due a concomitant and rapid increase of the prevalence rate of
ESBL-E worldwide and the perspective of a paucity of novel anti-
Gram-negative molecules (3, 4).
The ESBLNDP test has been developed recently for rapid iden-
tiﬁcation of ESBL-E (5). This test, based on the detection of hy-
drolysis of the-lactam ring of cefotaxime, an extended-spectrum
cephalosporin, is rapid, sensitive, and speciﬁc (5). Results are ob-
tained within less than 1 h, long before any antibiotic testing re-
sults are obtained (ca. 6 to 24 h). The ESBL NDP test has previ-
ously been validated using cultured bacteria (5). Here, the test has
been evaluated prospectively for its ability to detect ESBL-E re-
sponsible for UTIs directly from urine samples. Results showed
that this test used directly with infected urine samples might be a
useful guide for choosing a ﬁrst-line antibiotic therapy.
(This workwas presented to the EuropeanCongress of Clinical
Microbiology and Infectious Diseases [ECCMID] in 2013 in Ber-
lin, Germany.)
MATERIALS AND METHODS
Patient samples. Over a 4-month period (June to November 2012), all
urine samples sent to the Microbiology laboratory of the hospital Bicêtre,
a 950-bed university hospital in a suburb of Paris, France, were tested.
Urine samples were analyzed for the presence of leukocytes and bacteria.
First, leukocytes were manually counted using Kova slides (Hycor Bio-
medical, Penicuit, United Kingdom) and interpreted as recommended
(UTImore than 104 leukocytes/ml [6]). Gram staining and microscope
reading were done on all urine samples with more than 104 leukocytes/ml
by examining 50 ﬁelds. The presence of 1 or more microorganisms per
ﬁeld after observation of at least 20 ﬁelds was considered a positive result
corresponding to more than 105 Gram-negative bacteria/ml. The precise
number of bacteria present in the urine samplewas subsequently obtained
by serial dilutions and plating on UriSelect 4 medium (Bio-Rad, Marnes-
la-Coquette, France). CFU were counted after 24 h of incubation at 37°C.
Only urine samples recovered from UTI due to Gram-negative bacilli
(104 leukocytes/ml and positive Gram-negative staining) were included
in the study.
ESBL NDP test using urine samples. The ESBL NDP test was per-
formed with 500 urine samples during the study period. The protocol of
the ESBL NDP test for detection of the ESBL-E in urine samples was
adapted from the original protocol published previously (5). First, 4.5 ml
of urine specimen was transferred into three 1.5-ml Eppendorf tubes
(tubes A, B, and C) (each tube containing 1.5 ml of urine). After a centrif-
ugation at 13,000 gduring 2min, the supernatantwas discarded and the
bacterial pellet was resuspended in 500l of distilled water. After a second
centrifugation at 13,000 g for 2 min, the supernatant was discarded and
the bacterial pellet was resuspended in 100 l of Tris-HCl lysis buffer
(B-PER II bacterial protein extraction reagent; Pierce/Thermo Scientiﬁc,
Villebon-sur-Yvette, France) (20 mM). Then, 10 l of a concentrated
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tazobactam solution (40 mg/ml) was added to tube C. In tube A (internal
control), 100l of the revealing solution containing a pH indicator (phe-
nol red) was added. In tubes B and C (test tubes), 100 l of an extempo-
raneously prepared revealing solution supplemented with cefotaxime at 6
mg/ml was added. Tubes A, B, and C were incubated at 37°C for a maxi-
mumof 15min.Optical reading of the color change of each tubewas used.
The ESBL activity was detected through the transformation of cefotaxime
into a carboxylic form, leading to a pHdecrease revealed by a color change
(red to yellow/orange) in tube B, and inhibition of this reaction by tazo-
bactam leading to no color change in tube C. The results of the ESBL NDP
test were interpreted as follows: (i) when tubes A, B, and C were red, a
non-ESBL-producing isolate was present; (ii) when tubeAwas red, tube B
was yellow/orange, and tube C was red, an ESBL-producing isolate was
present; (iii) when tube A was red, tube B was yellow/orange, and tube C
was yellow/orange, a cephalosporinase-producing strain or a cephalospo-
rinase-plus-ESBL-producing strain was present; and (iv) when tubes A, B,
and C were yellow/orange, the result was not interpretable. The phenol
red revealing solutionwas prepared as previously described (5). A series of
10 negative and 10 positive isolates (CTX-M-producing strains) were in-
cluded in the study.
ESBL NDP test on colonies. After 24 h of incubation, the ESBL NDP
test was performed on bacterial cultures recovered on UriSelect 4 nonse-
lective chromogenic medium (Bio-Rad). Brieﬂy, 100 l of Tris-HCl lysis
buffer (B-PERII) (20 mM) was added in three 1.5-ml Eppendorf tubes (A,
B, andC). Then, one-fourth to one-third of a single calibrated inoculation
loop (10l) of bacterial colonies was resuspended in each of those 100 l
of Tris-HCl lysis buffer (20 mM). The ﬁnal step of the protocol was iden-
tical to that described above.
Antibiotic susceptibility testing. Antibiotic susceptibility testing of
bacterial colonies grown on UriSelect 4 (Bio-Rad) was performed by the
disc diffusion method following the EUCAST recommendations. Results
of the antibiogram (obtained at day 2) were interpreted according to the
EUCAST breakpoints (www.eucast.org/clinical_breakpoints/), as up-
dated in 2014. Since no EUCAST breakpoints have been determined for
temocillin, those of the British Society for Antimicrobial Chemotherapy
(susceptible,8mg/liter in systemic infections and32mg/liter inUTIs)
were used. MICs of cefotaxime, ceftazidime, and cefepime were deter-
mined on Muller-Hinton (MH) agar and MH agar supplemented with 4
g/ml of tazobactam, respectively.
ESBL phenotypic detection. The double-disk synergy test (DDST)
was performed for the phenotypic detection of ESBL producers according
to the EUCAST recommendations, using cefotaxime, ceftazidime, ce-
ﬁxime, and cefepime disks on the one hand and a disk containing ticar-
cillin plus clavulanate on the other hand. For species naturally producing
inducible AmpC (Enterobacter spp., Serratia spp., Morganella spp., Provi-
dentia spp., and Citrobacter freundii), the DDST was also performed on
cloxacillin (150 g/ml)-containing MH agar plates (bioMérieux). The
production of ESBLs was inferred by a synergy image as previously de-
scribed (7, 8). A DDST was performed in parallel to the antibiogram.
Molecular characterization of ESBLs. ESBL producers that have been
also detected with the DDST were submitted to molecular characteriza-
tion of the ESBL-encoding genes. Whole-cell DNAs were extracted using
aQIAmpminikit (Qiagen, Les Ulis, France). PCR ampliﬁcations followed
by sequencing of the entire -lactamase genes were performed for blaTEM
and blaSHV and for blaCTX-M and blaOXA using previously described prim-
ers (9).
RESULTS
Epidemiology of UTIs caused by ESBL-producing Enterobacte-
riaceae.Among the urine samples thatwere sent to the laboratory,
500 were positive for104 leukocytes/ml and positive for Gram-
negative isolates after Gram staining (meaning105 Gram-nega-
tive isolates/ml after culture). Among those 500 urine samples
corresponding to Gram-negative bacilli, 450 were considered
nonduplicate specimens. Among those 450 samples, 51 (11.3%)
were positive for ESBL-E using the DDST (conﬁrmed by PCR
ampliﬁcation and sequencing) as the reference technique. The
percentage of UTI caused by ESBL-E was signiﬁcantly higher for
males (16.9%) than for females (8.9%) (P of 0.02) (Table 1).
However, no signiﬁcant difference could be observed between the
three classes of age (0 to 15 years, 16 to 65 years, and65 years)
(Table 1). In addition, the percentages of ESBL-E isolated from
urine recovered from micturition (9.2%) and from urinary cath-
eters (15.2%) did not differ signiﬁcantly (Table 1). The rates of
UTIs caused by ESBL-Ewere similar (average 11.3%) regardless
of the hospital setting in which the patients were hospitalized,
except for the nephrology unit, where a signiﬁcantly higher pro-
portion was observed (35.7%, P of0.0001), and the gynecology/
obstetric unit, where a signiﬁcantly lower ratewas observed (0%,P
of0.05) (Table 1).
Among the 51 ESBL-E-related UTIs, 33 E. coli, 10 Klebsiella
pneumoniae, 5 Enterobacter cloacae, and 2 Citrobacter freundii iso-
lates and 1 Citrobacter koseri isolate were identiﬁed (Table 2). The
majority of the ESBLs identiﬁed were of the CTX-M type (49/51,
96.1%), with CTX-M-15 being predominant (35/51, 68.6%). A
single (E. coli) isolate produced two ESBLs (SHV-12 and CTX-M-
3). All ESBL-E were resistant to cefotaxime (the substrate used in
the ESBL NDP test) except a single E. coli isolate producing
TEM-24 (Table 2). These isolates were also resistant to other non-
-lactam antibiotics used for treating UTIs such as gentamicin
(64.7%), cotrimoxazole (83.3%), fosfomycin (27.5%), ciproﬂoxa-
cin (83.3%), amoxicillin plus clavulanate (29.4%), piperacillin
plus tazobactam (13.7%), cefoxitin (15.7%), and nitrofurantoin
(9.8%) and remained susceptible to all carbapenems (imipenem,
ertapenem, and meropenem) and to temocillin.
Results of the ESBL NDP test performed directly on urine
samples. Among the 450 nonduplicate urine specimens tested, the
ESBLNDPtestgave interpretable resultswith444samples (98.7%).A
positive resultwas obtained for 49 samples, and48were conﬁrmedas
representing ESBL-E (Fig. 1 andTable 2). A single urine sample con-
taining an E. coli isolate producing narrow-spectrum-clavulanic-
acid-resistant OXA-1 gave a false-positive result. The ESBL NDP
test gave negative results for 395 urine specimens that were all
negative for ESBL-E (Fig. 1). Among the six noninterpretable re-
sults, two results corresponded to urine samples containing
ESBL-E whereas four corresponded to urine samples without
ESBL-E. When performed directly on clinical urine samples with
104 leukocytes/ml and positive for Gram-negative isolates after
Gram staining (and including only interpretable results), the
ESBL NDP test had a sensitivity of 98%, a speciﬁcity of 99.8%, a
positive predictive value (PPV) of 98%, and a negative predictive
value (NPV) of 99.8%. Considering ESBL-E that were not de-
tected because of the classiﬁcation of noninterpretable results as
false negative, the ESBL NDP test had a sensitivity of 94.1%, a
speciﬁcity of 99.8%, a PPV of 98%, and a NPV of 99.3%.
Performance of the ESBL NDP test on cultured bacteria.
When performed on grown colonies recovered from urine sam-
ples at day 1, interpretable results were obtained for all specimens
with the ESBL NDP test. A total of 50 of the 51 ESBL-E specimens
were correctly detected using the ESBL NDP test. A TEM-24 pro-
ducer in E. coli isolates which did not confer resistance to cefo-
taxime was not detected (Table 2). No false-positive result was
obtained. When performed directly on cultured bacteria on
UriSelect medium, the ESBL NDP test showed a sensitivity of
98%, a speciﬁcity of 100%, a PPV of 100%, and a NPV of 99.8%.
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DISCUSSION
During this prospective study, 11.3% of those urine samples were
positive for ESBL-E. This rate is similar to the rate obtained in a
French survey of multidrug-resistant bacteria showing a rising
prevalence rate of ESBL-E (10). This rate correlates with the rate of
fecal carriage of ESBL-producing E. coli among healthy subjects
reported recently from the Paris area (11). The positivity rate for
ESBL-E that was observed formales was higher than that observed
for females, likely resulting from the nature of the UTI. In fact,
UTIs in males are usually associated with underlying diseases and
multiple episodes of treatment or/and hospitalization, which may
in turn result in higher multidrug resistance of the UTI isolates.
Although a rapid and global spread of CTX-M-type ESBL-E
has been observed since the 2000s, most of the ESBL-E recovered
in this study accordingly produced a CTX-M-type-lactamase, in
particular, CTX-M-15.
Here, we showed the technical feasibility of the use of the
ESBL-NDP test for determinations directly from urine samples.
The protocol of the ESBL NDP test ﬁrst devised with cultured
bacteria has been modiﬁed here and led to a shorter period of
detection, which was reduced from 60 min (5) to 15 min. Another
chromogenic test called the Cica--test or Lacta test (Bio-Rad)
has been recently developed for the rapid (15-min) detection of
Enterobacteriaceae resistant to expanded-spectrum cephalospo-
rins from cultures grown on agar media (12–14). A prospective
evaluation performed with the Lacta test on enterobacterial iso-
lates found sensitivity, speciﬁcity, PPV, and NPV values of 87.7%,
99.6%, 97.1%, and 98.2%, respectively (13). However, the Lacta
test cannot differentiate between resistance to expanded-spec-
trum-generation cephalosporins due to ESBL production and re-
sistance due to overexpressed (chromosomally encoded, plasmid-
acquired) AmpC. In addition, the Lacta test may also detect
TABLE 1 Characteristics of patient origins and ESBL producersa
Category and characteristic n (all)
Non-ESBL producer ESBL producer
Pn % n %
Patients
Total 450 399 88.7 51 11.3
Sex
Male 136 113 83.1 23 16.9 0.02
Female 314 286 91.1 28 8.9
Age (yr)
Total
0–15 32 31 96.9 1 3.1 ns
15–65 218 196 89.9 22 10.1
65 200 172 86.0 28 14.0
Male
0–15 11 11 100 ns
15–65 66 52 78.8 14 21.2
65 59 50 84.7 9 15.3
Female
0–15 21 20 95.2 1 4.8 ns
15–65 152 144 94.7 8 5.3
65 141 122 86.5 19 13.5
Department of hospitalization/consultation
Adult emergency 167 156 93.4 11 6.6 ns
Children emergency 28 27 96.4 1 3.6 ns
Intensive care 30 25 83.3 5 16.7 ns
Nephrology 42 27 64.3 15 35.7 0.0001
Hepatology 4 3 75 1 25 ns
Urology 22 17 77.3 5 22.7 ns
Geriatrics 6 4 66.7 2 33.3 ns
Orthopedic surgery 9 8 88.9 1 11.1 ns
Rheumatology 7 7 100 ns
Infectious diseases 40 35 87.5 5 12.5 ns
Gynecology/obstetrics 33 33 100 0.05
Endocrinology 8 8 100 ns
Cardiology 9 8 88.9 1 11.1 ns
Pneumatology 5 4 80 1 20 ns
Neurology 21 21 100 ns
Other 19 16 84.2 3 15.8 ns
Urine specimen
Urine sample source
Micturition 325 293 90.2 32 9.2 ns
Urinary catheter 125 106 84.8 19 15.2
a n, number of urine samples; ns, no signiﬁcant difference.
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several types of carbapenemases, raising the possibility of poten-
tial confusion betweendetection of carbapenemases anddetection
of ESBLs. The most recent study published using the Lacta test
reported on false-negative results obtained with AmpC overpro-
ducers, producers of ESBL at low levels, and producers of VIM-
type carbapenemase (14). In addition, theLacta test has not been
evaluated for detection of ESBL-E directly from clinical samples.
The rate of noninterpretable results with the ESBL NDP test is
very low (1.3%), making this test adequate for routine use. A sin-
gle negative result was obtained with a TEM-24 ESBL producer
(Table 2). Interestingly, this TEM-24 ESBL producer was suscep-
tible to cefotaxime. Therefore, all cefotaxime-resistant isolates
which were ESBL producers were perfectly detected by using the
ESBLNDP test. The unique false-positive result was obtainedwith
an OXA-1-producing E. coli isolate; however, this enzyme is not
an ESBL, sensu stricto, since its activity is not inhibited by clavu-
lanic acid whereas it hydrolyzes cefotaxime and cefepime when
overproduced (15). Of note, in our study, Gram staining and mi-
croscope reading were done systematically on all urine samples
with more than 104 leukocytes/ml, leading to inclusion of only
TABLE 2 Results of the ESBL NDP test performed with urine samples and from isolated colonies of EBSL producersa
Species CFU/ml -Lactamase content
ESBL NDP test
result for urine
samples
ESBL NDP test
result for
bacterial
colonies MIC (g/ml)
CTX
CTX
TZB CTX
CTX
TZB CTX
CTX
TZB CAZ
CAZ
TZB FEP
FEP
TZB
E. coli 1.2 · 106 CTX-M-1     8 0.125 2 0.016 3 0.023
E. coli 2 · 106 CTX-M-1     24 0.032 1.5 0.016 3 0.016
E. coli 3.8 · 107 CTX-M-1     32 0.25 2 0.25 12 0.023
E. coli 2.8 · 107 CTX-M-1 TEM-1     4 0.25 48 0.094 16 0.094
E. coli 1.1 · 107 CTX-M-1 TEM-1     48 0.19 2 0.125 6 0.032
E. coli 1.2 · 106 CTX-M-1 TEM-1     24 0.064 2 0.064 6 0.032
E. coli 1.1 · 107 CTX-M-3 SHV-12     48 0.125 24 0.19 12 0.047
E. coli 9.4 · 107 CTX-M-14     24 0.047 1 0.032 4 0.023
E. coli 2.8 · 108 CTX-M-14     32 0.047 4 0.094 3 0.032
E. coli 6 · 107 CTX-M-14 TEM-1     8 0.25 0.75 0.047 2 0.032
E. coli 1.3 · 106 CTX-M-15     256 0.19 8 0.125 12 0.032
E. coli 3.3 · 107 CTX-M-15     256 0.19 8 0.064 8 0.032
E. coli 9.8 · 107 CTX-M-15     192 0.25 32 0.125 12 0.19
E. coli 5.2 · 108 CTX-M-15     256 0.125 32 0.016 24 0.064
E. coli 4.1 · 107 CTX-M-15     192 0.094 16 0.064 12 0.047
E. coli 2.3 · 108 CTX-M-15     96 0.094 16 0.023 12 0.047
E. coli 2.8 · 107 CTX-M-15     256 0.032 6 0.016 6 0.023
E. coli 6.5 · 107 CTX-M-15     256 0.047 32 0.19 16 0.032
E. coli 5.3 · 107 CTX-M-15     256 0.047 12 0.047 12 0.032
E. coli 9.4 · 106 CTX-M-15     256 0.064 16 0.047 12 0.047
E. coli 1.6 · 107 CTX-M-15     256 0.047 12 0.094 12 0.023
E. coli 1.2 · 108 CTX-M-15     64 0.064 12 0.047 6 0.047
E. coli 1.8 · 107 CTX-M-15     256 0.032 128 0.064 128 0.047
E. coli 9.5 · 106 CTX-M-15 TEM-1     16 0.19 3 0.19 1.5 0.023
E. coli 2.1 · 108 CTX-M-15 TEM-1     64 0.19 24 0.125 12 0.032
E. coli 6.3 · 107 CTX-M-15 TEM-1     96 0.047 8 0.016 8 0.032
E. coli 6 · 108 CTX-M-15 TEM-1     256 0.047 32 0.094 16 0.032
E. coli 4 · 107 CTX-M-15 TEM-1     256 0.047 24 0.125 8 0.016
E. coli 6.2 · 108 CTX-M-15 TEM-1     256 0.38 64 0.25 32 0.094
E. coli 4 · 107 CTX-M-15 TEM-1     192 0.064 24 0.25 16 0.047
E. coli 3.4 · 107 CTX-M-15 TEM-1 NI NI   24 0.032 1 0.032 2 0.016
E. coli 9 · 108 CTX-M-27 TEM-1     2 0.064 256 0.125 6 0.047
E. colib 8.9 · 106 TEM-24     1 0.032 256 0.047 0.38 0.016
K. pneumoniae 3.1 · 106 CTX-M-1     16 0.064 2 0.064 3 0.016
K. pneumoniae 1.1 · 108 CTX-M-15 SHV-1     32 0.064 4 0.125 3 0.023
K. pneumoniae 2.3 · 108 CTX-M-15 SHV-1 TEM-1     256 0.064 64 0.125 24 0.047
K. pneumoniae 4.3 · 108 CTX-M-15 SHV-1 TEM-1     256 1.5 48 0.5 48 0.25
K. pneumoniae 3.7 · 107 CTX-M-15 SHV-1 TEM-1     48 0.19 8 0.047 3 0.032
K. pneumoniae 2.7 · 108 CTX-M-15 SHV-1 TEM-1     192 0.19 24 0.19 6 0.023
K. pneumoniae 1.3 · 108 CTX-M-15 SHV-1 TEM-1     48 0.032 24 0.032 6 0.047
K. pneumoniae 4.3 · 107 CTX-M-15 SHV-1 TEM-1 NI NI   256 0.047 8 0.064 6 0.023
K. pneumoniae 3.9 · 108 CTX-M-15 SHV-1 TEM-1     48 0.032 12 0.125 3 0.023
K. pneumoniae 3.1 · 107 CTX-M-15 SHV-1 TEM-1     192 0.125 96 0.75 12 0.094
C. freundii 2.3 · 108 CTX-M-15     256 0.032 24 0.023 8 0.023
C. freundii 1.8 · 107 CTX-M-3     256 0.032 16 0.023 128 0.016
C. koseri 2.1 · 107 CTX-M-1     16 0.023 1.5 0.016 32 0.016
E. cloacae 5.1 · 107 CTX-M-15     256 16 256 8 48 1
E. cloacae 5 · 107 CTX-M-15 TEM-1     256 192 256 64 64 1.5
E. cloacae 1.5 · 108 CTX-M-15 TEM-1     256 1.5 48 0.75 48 0.19
E. cloacae 1.1 · 107 CTX-M-15 TEM-1     256 0.38 256 0.064 96 0.19
E. cloacae 1.4 · 108 SHV-12 TEM-1     6 0.19 256 0.119 2 0.047
a CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; TZB, tazobactam. ESBLs are indicated in bold., yellow/orange;	, red; NI, not interpretable. EUCAST breakpoints were1
and2 g/ml for cefotaxime,1 and4 g/ml for ceftazidime, and1 and4 g/ml for cefepime.
b This E. coli isolate produced TEM-24, an ESBL that does not hydrolyze cefotaxime.
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those urine samples recovered from true UTI due to Gram-nega-
tive bacilli. Accordingly, since several laboratories do not doGram
staining on urine samples, the results of the ESBL NDP test per-
formed directly on all urine samples might differ slightly.
Detection of those ESBL-E that are resistant to cefotaxime by
using the ESBL NDP test is perfect. Therefore, by using the ESBL
NDP test, we may not only detect ESBL producers for epidemio-
logical purposes as recommended by the EUCAST and CLSI but
also guide the ﬁrst choice of antibiotherapy. For instance, temo-
cillin might be an alternative to carbapenems for treatment as well
as -lactam/-lactam inhibitors such as the promising combina-
tion of ceftazidime plus avibactam. Its use may also reduce the
median length of hospitalization due to the delay in introducing
the appropriate therapy for treating infections due to ESBL-E
(16–19).
In areas with a high prevalence of carbapenemase producers,
the rapid Carba NP test could also be performed, for instance, for
detection of KPC producers that may give positive results for both
the ESBL NDP test and the Carba NP test; since those special
carbapenemases hydrolyze both carbapenems and cefotaxime,
with this hydrolytic activity being inhibited by clavulanic acid
(20). The ESBL NDP test will give negative results in the presence
of a carbapenemase with metallo--lactamase (hydrolysis of cefo-
taxime but no inhibition by clavulanic acid) as well as with a car-
bapenemase of the OXA-48 type (no hydrolysis of cefotaxime).
Fortunately, a low prevalence of carbapenemase producers as a
source of UTIs is observed in the United States and many Euro-
pean countries. The latest study performed in France reported a
0.01% incidence of carbapenemase-producing E. coli infections
(21).
The use of the ESBL NDP test directly on clinical samples pro-
vides useful guidance for implementation of hygiene controlmea-
sures at the early stage of the hospitalization (at day 0 and not 48 h
later) in cases in which it shows positivity in particular for ESBL
producers with respect to K. pneumoniae, which is the main spe-
cies responsible for ESBL-E outbreaks (22).
As a conclusion, we may be at the edge of a change of paradigm
by detecting biochemical activity (ESBL or carbapenemase) di-
rectly from clinical samples and then waiting for conﬁrmatory
results from susceptibility testing.
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